Serial #79225044
LIVE

Serial Number

79225044

Owner

Ascendis Pharma A/S

Attorney

Shannon Marie McKeon

Filing Date

Oct 11, 2017

Add to watchlist:

No watchlists yet
View on USPTO

Serial #79225044 Trademark

Serial Number: 79225044 • Registration: 5671918

Serial #79225044 is a trademark filed by Ascendis Pharma A/S on October 11, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services). The application is currently registered and active.

Owner Contact Info

Ascendis Pharma A/S (9 trademarks)

Tuborg Boulevard 5
Hellerup 2900 , DK

Entity Type: 16

Trademark Details

Filing Date

October 11, 2017

Registration Date

February 12, 2019

Published for Opposition

November 27, 2018

Goods & Services

Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology; pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides

Licensing of industrial property; legal services

Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology

Filing History

NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jun 20, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jun 20, 2025 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 2, 2025 APRE
TEAS SECTION 71 & 15 RECEIVED
Feb 12, 2025 ES75
NEW REPRESENTATIVE AT IB RECEIVED
Mar 10, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 12, 2024 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Dec 24, 2021 NREP
NEW REPRESENTATIVE AT IB RECEIVED
Oct 28, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Jun 21, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jun 4, 2019 FICS
FINAL DISPOSITION PROCESSED
Jun 4, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 12, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 12, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 27, 2018 NPUB
PUBLISHED FOR OPPOSITION
Nov 27, 2018 PUBO
NOTIFICATION PROCESSED BY IB
Nov 24, 2018 GPNX
REFUSAL PROCESSED BY IB
Nov 16, 2018 RFNT
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Nov 7, 2018 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Nov 7, 2018 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 7, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 17, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 28, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 27, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 27, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 17, 2018 GNRN
NON-FINAL ACTION E-MAILED
Sep 17, 2018 GNRT
NON-FINAL ACTION WRITTEN
Sep 17, 2018 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 17, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 17, 2018 CRFA
ASSIGNED TO LIE
Aug 16, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2018 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 24, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 24, 2018 REAP
REFUSAL PROCESSED BY IB
Feb 16, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 1, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 1, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 25, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jan 24, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 23, 2018 MAFR
ASSIGNED TO EXAMINER
Jan 19, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 19, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 18, 2018 REPR